Fishman Jay A Ltd. MI Has $30.83 Million Stock Holdings in Stryker Corporation $SYK

Fishman Jay A Ltd. MI lifted its stake in Stryker Corporation (NYSE:SYK) by 1.1% during the second quarter, HoldingsChannel reports. The fund owned 77,922 shares of the medical technology company’s stock after purchasing an additional 815 shares during the quarter. Stryker comprises approximately 3.0% of Fishman Jay A Ltd. MI’s holdings, making the stock its 11th biggest position. Fishman Jay A Ltd. MI’s holdings in Stryker were worth $30,828,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Brighton Jones LLC increased its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Vest Financial LLC acquired a new position in Stryker during the first quarter worth $203,000. Procyon Advisors LLC increased its position in Stryker by 2.3% during the first quarter. Procyon Advisors LLC now owns 2,611 shares of the medical technology company’s stock worth $972,000 after buying an additional 59 shares during the last quarter. SeaCrest Wealth Management LLC increased its position in Stryker by 27.6% during the first quarter. SeaCrest Wealth Management LLC now owns 1,497 shares of the medical technology company’s stock worth $557,000 after buying an additional 324 shares during the last quarter. Finally, Sivia Capital Partners LLC increased its position in Stryker by 4.0% during the first quarter. Sivia Capital Partners LLC now owns 1,070 shares of the medical technology company’s stock worth $398,000 after buying an additional 41 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on SYK. Wells Fargo & Company increased their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Rothschild & Co Redburn started coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Stryker in a report on Saturday, September 27th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Finally, Truist Financial set a $415.00 price target on shares of Stryker and gave the company a “hold” rating in a report on Monday, August 4th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $430.33.

Stryker Stock Up 1.1%

NYSE SYK opened at $370.59 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a 50-day simple moving average of $382.81 and a 200 day simple moving average of $378.96. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market cap of $141.68 billion, a PE ratio of 49.08, a PEG ratio of 2.67 and a beta of 0.94.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter last year, the company earned $2.81 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.